About Celgene
Celgene is a company based in Summit (United States) founded in 1986 was acquired by Bristol-Myers Squibb in January 2019. Celgene has raised $45 million across 8 funding rounds from investors including Mesoblast, Bristol-Myers Squibb and Geneva Partners. The company has 4,891 employees as of December 31, 2020. Celgene has completed 11 acquisitions, including Abraxis BioScience, Acetylon and Avila Therapeutics. Celgene operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Summit, United States
- Employees 4891 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Celgene
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$45 M (USD)
in 8 rounds
-
Latest Funding Round
$4.1 M (USD), Post-IPO
Feb 10, 2018
-
Investors
Mesoblast
& 3 more
-
Employee Count
4891
as on Dec 31, 2020
-
Investments & Acquisitions
Abraxis BioScience
& 10 more
-
Acquired by
Bristol-Myers Squibb
(Jan 03, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Celgene
Unlock access to complete
Unlock access to complete
Leadership Team
394 people
Software Development Team
340 people
Senior Team
99 people
Product Management Team
97 people
Operations Team
83 people
Data Analysis and Operations Team
60 people
Sales and Marketing
58 people
Human Resources and Administration
45 people
Unlock access to complete
Funding Insights of Celgene
Celgene has successfully raised a total of $45M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.1 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Celgene
Celgene has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Mesoblast, Bristol-Myers Squibb and Geneva Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Offers comprehensive investment advisory and financial planning services to clients.
|
Locked | Locked | Locked | |
|
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
Locked | Locked | Locked | |
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for Celgene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celgene
Celgene has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Abraxis BioScience, Acetylon and Avila Therapeutics.
Investment portfolio details for Celgene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Regulatory T cell therapeutics for autoimmune diseases are developed.
|
Locked | Locked | 2015 | Locked | |
|
T-cell bispecific antibodies are developed for cancer treatment.
|
Locked | Locked | 2013 | Locked | |
|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Celgene
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Celgene
Detailed financials for Celgene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celgene Comparisons
Peer comparison for Celgene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celgene
Celgene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| Locked | Locked | Locked |
Outsourced contract research organization services are provided to clients.
|
Detailed competitors of Celgene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celgene
Complete news archive for Celgene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celgene
Celgene was founded in 1986 and raised its 1st funding round 22 years after it was founded.
Celgene is headquartered in Summit, United States.
Sol J. Bare is the current CEO of Celgene.
Celgene is a funded company, having raised a total of $45M across 8 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Celgene is 4,891.
Celgene is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer. The companys lead molecule BCMA CAR T is used for treating multiple myeloma. The candidate is in phase II clinical study. Other candidates are in phase I and II, used for treating various cancers. In 2018, the company recorded annual revenues of 15.28B, and a net profit of 4.04B.
Celgene's top competitors include Juno Therapeutics, Lyell Immunopharma and Autolus.
Celgene has made 11 acquisitions, including Abraxis BioScience, Acetylon, and Avila Therapeutics.
Celgene has 4 investors. Key investors include Mesoblast, Bristol-Myers Squibb, Geneva Partners, and Military Health.